RA0419

antibody from Oursmab

Targeting: INSR CD220

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0419

Provider

Oursmab

Product name

Ersodetug (Biosimilar Reference Antibody) (INSR)

Antibody type

Monoclonal

Description

Ersodetug is an investigational, fully human monoclonal antibody developed as a novel therapy for congenital and acquired forms of Hyperinsulinism (HI), a condition characterized by excessive and dysregulated insulin secretion leading to severe hypoglycemia. It functions through a unique, allosteric mechanism of action. Unlike traditional insulin receptor antagonists that directly compete with insulin for binding, ersodetug binds to a distinct, allosteric site on the insulin receptor (IR). This binding negatively modulates the receptor's signaling in response to insulin or related hormones (such as IGF-1 and IGF-2). By acting as a negative allosteric modulator, it effectively dampens the downstream signaling cascade (e.g., through the PI3K/Akt pathway) that would otherwise be overactivated in HI, thereby reducing the inappropriate cellular responses (like excessive glucose uptake and inhibition of gluconeogenesis) that cause dangerous low blood sugar.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.